Introduction Clinical Depression and the subsequent low immunity is a comorbidity that can
act as a risk factor for the severity of COVID-19 cases. Antidepressants such as Selective …

The COVID-19 pandemic has encouraged the repurposing of existing drugs as a shorter
development strategy in order to support clinicians with this difficult therapeutic dilemma …

Objective To examine differences in mortality and/or severe acute respiratory syndrome
between selective serotonin reuptake inhibitor-(SSRI) users and non-SSRI users up to 60 …

Abstract The World Health Organization has proposed that a search be made for alternatives
to vaccines for the prevention and treatment of COVID-19, with one such alternative being …

Abstract Background and Aim Due to the high social and economic burden and also
mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few …

Although Coronavirus disease (COVID-19) infection is primarily associated with fever,
respiratory symptoms, pneumonia, and acute respiratory distress syndrome, the virus …

The rapid spread of COVID-19 has become a health emergency causing an urgent need for
drug treatments to control the outbreak, especially in more vulnerable individuals. This is …

In the last 2 years, different pharmacological agents have been indicated as potential
inhibitors of SARS‐CoV‐2 in vitro. Specifically, drugs termed as functional inhibitors of acid …

Background: SARS-CoV-2 main protease (Mpro or 3CLpro) and papain-like protease
(PLpro) are common viral targets for repurposed drugs to combat COVID-19 disease …

2019 (COVID-19), many efforts have been made to prevent and to treat the disease. In this
line, the anti-inflammatory effect of selective serotonin reuptake inhibitors (SSRI) as …